Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Angelica Loskog is active.

Publication


Featured researches published by Angelica Loskog.


The Journal of Urology | 2001

POTENT ANTITUMOR EFFECTS OF CD154 TRANSDUCED TUMOR CELLS IN EXPERIMENTAL BLADDER CANCER

Angelica Loskog; Anna Björkland; Michael P. Brown; Olle Korsgren; Per-Uno Malmström; Thomas H. Tötterman

PURPOSEnCurrent intravesical immunotherapy for bladder cancer with bacillus Calmette-Guerin instillations is standard treatment for patients with high risk superficial tumors but relapses are common. We evaluated the tumor vaccine concept in murine bladder cancer by comparing tumor cell transduction with genes coding for the immunostimulatory molecules CD154, interleukin (IL)-12 and CD80 to design a novel vaccination strategy.nnnMATERIALS AND METHODSnAdenoviral vectors were used to transduce murine bladder cancer MB-49 cells with genes coding for CD154, IL-12 and CD80. Parental or transduced MB-49 cells were injected subcutaneously into syngeneic mice. The effects of transgene expression on tumorigenicity and the generation of protective immunological memory against challenge with parental tumor were studied.nnnRESULTSnAll 76 animals injected with parental MB-49 cells had tumors within 8 to 12 days. Tumor cell expression of CD154 combined with IL-12 completely inhibited tumor outgrowth with all 21 mice tumor-free and CD154 transduction alone was almost as effective with 33 of 35 tumor-free. IL-12 production by tumor cells delayed tumor outgrowth and 4 of 10 mice remained tumor-free. Over expression of CD80 had no effect on tumorigenicity. CD154 expressing tumors were rapidly infiltrated with large numbers of CD4+ and CD8+ T cells. Mice vaccinated 4 times with adenoviral CD154 transduced MB-49 cells were completely protected against challenge with parental tumor. Co-injection of CD154 modified cells with parental MB-49 cells retarded tumor growth.nnnCONCLUSIONSnOur experimental results suggest that the potent antitumor effects of CD154 gene transduction should be considered for immunostimulatory gene therapy for bladder cancer.


Archive | 2010

NEW MEDICAL METHODS AND AGENTS FOR USE THEREIN

Thomas H. Tötterman; Linda Sandin; Angelica Loskog; Sara M. Mangsbo; Peter Ellmark


Archive | 2017

Diffusion-Weighted MRI may be better than FDG-PET/CT to assess immunotherapy response in patients with metastatic melanoma

Aglaia Schiza; Sandra Irenaeus; Francisco Ortiz-Nieto; Angelica Loskog; Thomas H. Tötterman; Anders Sundin; Gustav Ullenhag; Håkan Ahlström


Archive | 2017

Proximity extension assay-based plasma proteomics cannot predict relapse in chronic myeloid leukaemia patients stopping treatment with tyrosine kinase inhibitors (TKI) but reveal profound effects of long-term TKI treatment on plasma protein profiles

Stina Söderlund; Inger Persson; Mette Ilander; Joelle Guilhot; Henrik Hjorth-Hansen; Johan Richter; Susanne Saussele; Satu Mustjoki; Angelica Loskog; Ulla Olsson-Strömberg


Archive | 2014

CARs expressing CD28 and 4-1BB demonstrate increased intracellular signaling activity and proliferative capacity while maintaining a memory phenotype upon repeated antigen stimulation

Hannah Karlsson; Emma Svensson; Camilla Gigg; Rolf Larsson; Malin Jarvius; Ulla Olsson-Strömberg; Barbara Savoldo; Gianpietro Dotti; Angelica Loskog


Archive | 2014

CAR T Cells Induce DC Maturation via a Cell Contact-dependent Process and Enhance Their Ability to Stimulate T Cell Responses

Hannah Karlsson; Wictor Gustafsson; Ulla Olsson-Strömberg; Barbara Savoldo; Gianpietro Dotti; Angelica Loskog


Archive | 2014

Third Generation CD28/4-1BB CAR T Cells for Refractory CD19+ B Cell Malignancy: Generation of a GMP Protocol an Evaluation of Clinical Grade Batches

Hannah Karlsson; Gunilla Enblad; Kristina Wikström; Charlotte Hållstrand; Heidi Pettersson; Pontus Blomberg; Magnus Essand; Rose-Marie Amini; Malcolm K. Brenner; Barbara Savoldo; Gianpietro Dotti; Hans Hagberg; Angelica Loskog


Archive | 2013

A Comparison of Multiplex Platforms for Absolute and Relative Protein Quantification

Lisa Christiansson; Satu Mustjoki; Angelica Loskog; Sara M. Mangsbo


Archive | 2013

Imatinib or dasatinib treatment of chronic myeloid leukemia reduces circulating myeloid-derived suppressor cells but increases their CD40 expression

Lisa Christiansson; Stina Söderlund; Henrik Hjorth-Hansen; Martin Höglund; Berit Markevärn; Johan Richter; Leif Stenke; Bengt Simonsson; Satu Mustjoki; Angelica Loskog; Ulla Olsson-Strömberg


Archive | 2010

Peripheral T Lymphocytes, Including FoxP3+ T-Cells, Exhibit a Cytotoxic Phenotype in Patients with B-Cell Lymphoma

Camilla Lindqvist; Lisa Christiansson; Gunilla Enblad; Angelica Loskog

Collaboration


Dive into the Angelica Loskog's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Barbara Savoldo

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Gianpietro Dotti

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge